drcamidge.bsky.social
Oncologist, writer, ‘How This is Building Me’ Onclive podcast host - fan of truth, creativity and humor
https://podcasts.apple.com/us/podcast/how-this-is-building-me/id1726421043
184 posts
292 followers
164 following
Regular Contributor
Active Commenter
comment in response to
post
I quoted seal at her. “We’re never gonna survive unless we get a little crazy” - I strongly believe she has no idea what I am referring to.
comment in response to
post
She was already leading a charm offensive for her son Jackson, advocating for those with cerebral palsy - so cancer was just another thing to fold into her exuberant world of changing hearts and minds for the better
comment in response to
post
I first met Summer at an ALK lung cancer patient summit - her energy, fun and laughter filled the room. Her dad lovingly calls her a train wreck but it’s a train you want to get on
comment in response to
post
I miss some of the smaller, intimate quirkiness of this from past meetings but not the extra ‘of’ in the title…
comment in response to
post
This has run for over 20 years but this is the first time at this venue. The older fair month hotel in Santa Monica used to be the whole but size expansion was needed. For years its title was also a celebration of English inattention. “Targeted Therapies of the treatment of lung cancer”
comment in response to
post
See you soon
comment in response to
post
Espouses only this form. Opposes all other forms.
comment in response to
post
Warriors come in many forms. Their passion, like Mike Kelley’s, is their strength. And let’s not forget the role that gibbons played in all of this
comment in response to
post
Dr Kelley feels passionately about its potential to deliver the best cancer care, to this complex population within the unique setting of sanctioned socialized medicine in a country that espouses socialized medicine when it’s referred to as such.
comment in response to
post
The VA, speaking as one brought up in another country and another healthcare system, is a marvel and a contradiction. Healthcare free at the point of delivery to vast numbers of the US population, telehealth without restrictions across state borders, a unified electronic medical record.
comment in response to
post
Mike Kelley who now runs national cancer services in the VA, is one of the good guys. Humble, self-deprecating but driven to care for the veterans of the USA with cancer.
comment in response to
post
But if you are before the median yes have the discussion about switching
comment in response to
post
If you are clearly past the median, clearly onto some kind of plateau you have already found your drug. You don’t need to change…
comment in response to
post
The answer is, it depends, for every initial ALK tki there is a population that does really really well for a long time. The good ALKs or gALKs. Look at that crown data again. There are gALKs even with crizotinib (green box).
comment in response to
post
Lorlatinib hasn’t suddenly become better tolerated or easier to give based on its labeled starting dose (but that’s another story). The issue is should anyone on brigatinib or alectinib or anything else other than lorlatinib in the first line switch to lorlatinib even if they are doing well?
comment in response to
post
But it’s not the first choice now. Lorlatinib is due to its prolonged initial control in the CROWN study (longer than it’s expected sequential control if its used second line)
comment in response to
post
comment in response to
post
The rarest of self-righting duckies in the water feature as well!
comment in response to
post
Dr Sasaki took on the challenge of bringing cancer care to those on the edges with passion and ingenuity- we should all have pioneers like her in the underdeveloped frontiers of health care.
comment in response to
post
In many cities there are safety net hospitals - care funded by the city for those most in need. The uninsured, the unhoused, the undocumented. In Denver, where are dominant minorities are Hispanic, that safety net is ‘Denver Health’
comment in response to
post
Given the risks of biotech startups- how do you move on after an asset goes under? Shawn is the Rocky Balboa inspiration for me in this setting - it ain’t how hard you can hit, it’s how hard you can be hit and keep moving forward. That’s what winners do.
comment in response to
post
The pubmed link should work. If not send me your email and I’ll send manuscript. For atomic google it with the word ‘criterium’ for all the consortia
comment in response to
post
In this paper one of our MVPs David Gerber from UTSW pulled all ten years of our IIT data. 25percent get funded, median budget 2 million (up to nearly 8 million), tight timelines, guidance for what works and a generation of grown opinion leaders 💚 Baboom
comment in response to
post
ATOMIC and its sister consortia in gi, breast and gu cancers filled that gap. A full service CRO to coordinate, to negotiate budget and to allow the members to craft the research and mentor each other was and is the heart of each.
comment in response to
post
But then the molecular revolution happened and there were no common cancers. All feasible studies had to be multisite. And that meant much bigger budgets for the coordination.
comment in response to
post
Pharma had always supported some investigator initiated trials (where the Md still owned the data and ran the study) but these, at their worst, were a goodie to give an MD more than a hope that a meaningful result would emerge. Their 500k cap was fine when you could find common cancers everywhere